MoonLake Ebitda from 2010 to 2024

MLTX Stock  USD 54.43  0.19  0.35%   
MoonLake Immunotherapeuti EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, MoonLake Immunotherapeuti EBITDA regression line of annual values had significance of  0 and arithmetic mean of (11,742,200). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-54.1 M
Current Value
-51.4 M
Quarterly Volatility
23.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 K, Other Operating Expenses of 34.1 M or Total Operating Expenses of 34.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.28. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
  
Check out the analysis of MoonLake Immunotherapeuti Correlation against competitors.

Latest MoonLake Immunotherapeuti's Ebitda Growth Pattern

Below is the plot of the Ebitda of MoonLake Immunotherapeutics over the last few years. It is MoonLake Immunotherapeuti's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

MoonLake Ebitda Regression Statistics

Arithmetic Mean(11,742,200)
Coefficient Of Variation(200.43)
Mean Deviation18,044,912
Median(90,838)
Standard Deviation23,534,886
Sample Variance553.9T
Range65M
R-Value(0.70)
Mean Square Error307.3T
R-Squared0.48
Significance0
Slope(3,664,353)
Total Sum of Squares7754.5T

MoonLake Ebitda History

2024-51.4 M
2023-54.1 M
2022-65 M
2021-4.6 M

About MoonLake Immunotherapeuti Financial Statements

MoonLake Immunotherapeuti investors use historical fundamental indicators, such as MoonLake Immunotherapeuti's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MoonLake Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-54.1 M-51.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.